(DCPH) – Analyst Ratings
-
JPMorgan Reinstates Deciphera (DCPH) at Neutral
-
Jones Trading Upgrades Deciphera (DCPH) to Buy, sees higher probability of success for vimseltinib
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to DCPH Stock Lookup